유럽의 마이크로바이옴 치료 시장 예측(-2030년) : 지역별 분석 - 유형, 용도 및 최종 사용자별 분석

The Europe microbiome therapeutics market was valued at US$ 97.74 million in 2022 and is expected to reach US$ 212.52 million by 2030; it is estimated to record a CAGR of 10.2% from 2022 to 2030.

Inflow of Funds to Ameliorate Microbiome Discovery Pipeline Drives Europe Microbiome Therapeutics Market

Research has shown that imbalances or disruptions in the microbiome can contribute to various conditions, such as inflammatory bowel disease and obesity, as well as mental health disorders. The recognition of the microbiome's role in overall health has generated significant interest in developing therapeutics to target and modulate the microbiome. Additionally, advancements in technology and research tools have made it easier to study and manipulate the microbiome. Next-generation sequencing and metagenomic analysis have allowed for a deeper understanding of microbial communities and their functions. The increased knowledge has opened up new possibilities for developing targeted therapies. For instance, in March 2023, mbiomics GmbH, a German microbiome biotech company, developed the first generation of effective microbiome-based therapeutics. It received a funding of 13 million (US$ 15 million) from MIG Capital. The funding will allow to build the platform, which will accelerate the identification of first-lead drug candidates and speed up research efforts toward clinical validation. As strong clinical evidence becomes available, investors are beginning to take notice of microbiome modulator firms. The heightened funding provides companies with necessary resources to overcome the challenges associated with the high cost of development and production, ultimately driving the field forward.

Europe Microbiome Therapeutics Market Overview

Microbiome therapeutic research companies in Germany are focused on calling other companies to invest in their research activities to improve the quality of research being conducted for microbiome product development. In March 2023, mbiomics GmbH, a German biotech company focused on the microbiome, received ~US$ 15 million (13 million) in a series A financing round led by MIG Capital. mbiomics used the proceeds to embark on strategic partnerships, significantly expanding their Munich laboratory facilities and R&D teams in Germany. In some FMT procedures, infectious agents may be transferred from donor to patient, which affects the outcomes. Hence, Germany has set particular regulations for the use of microbiome or FMT procedures. In Germany, FMT drugs are regulated as a medicinal product; however, the use of this product can be done only when no other treatment is working on conditions such as C. difficile infections and gut infections. Hence, despite an upsurge in investments in research on microbiome therapeutics, regulations regarding the use of these therapeutic products may hamper the growth of the Europe microbiome therapeutics market in Germany.

Europe Microbiome Therapeutics Market Revenue and Forecast to 2030 (US$ Million)

Europe Microbiome Therapeutics Market Segmentation

The Europe microbiome therapeutics market is segmented based on type, application, end user, and country.

Based on type, the Europe microbiome therapeutics market is bifurcated into therapeutics and procedure. The procedure segment held a larger share in 2022. The therapeutics segment is further subsegmented into fecal microbiota transplantation (FMT), prebiotics & probiotics, and others.

By application, the Europe microbiome therapeutics market is segmented into metabolic disorder and obesity, C. difficile infection, inflammatory bowel disease, and others. The metabolic disorder and obesity segment held the largest share in 2022.

By end user, the Europe microbiome therapeutics market is hospitals and clinics, ambulatory surgical centers, homecare, and others. The hospitals and clinics segment held the largest share in 2022.

Based on country, the Europe microbiome therapeutics market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe microbiome therapeutics market in 2022.

Caelus Health BV, Enterome SA, Ferring Holdings SA, Vedanta Biosciences Inc, and YSOPIA Bioscience SA are some of the leading companies operating in the Europe microbiome therapeutics market.

Table Of Contents

1. Introduction

• 1.1 The Insight Partners Research Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Key Insights

3. Research Methodology

• 3.1 Coverage
• 3.2 Secondary Research
• 3.3 Primary Research

4. Europe Microbiome Therapeutics Market Landscape

• 4.1 Overview
• 4.2 Europe PEST Analysis

5. Europe Microbiome Therapeutics Market - Key Industry Dynamics

• 5.1 Europe Microbiome Therapeutics Market - Key Industry Dynamics
• 5.2 Key Market Drivers
  • 5.2.1 Potential of Gut Microbiota in Maintaining Human Health
  • 5.2.2 Inflow of Funds to Ameliorate Microbiome Discovery Pipeline
• 5.3 Key Market Restraints
  • 5.3.1 High Cost of Development and Production
• 5.4 Key Market Opportunities
  • 5.4.1 Increasing R&D to Gain Better Understanding of Human Microbiome
• 5.5 Key Future Trends
  • 5.5.1 Technological Advancement in Human Microbiome Therapeutics
• 5.6 Impact of Drivers and Restraints:

6. Microbiome Therapeutics Market - Europe Market Analysis

7. Europe Microbiome Therapeutics Market Analysis - Type

• 7.1 Therapeutics
  • 7.1.1 Overview
  • 7.1.2 Therapeutics Market, Revenue and Forecast to 2030 (US$ Thousand)
• 7.2 Procedure
  • 7.2.1 Overview
  • 7.2.2 Procedure Market, Revenue and Forecast to 2030 (US$ Thousand)

8. Europe Microbiome Therapeutics Market Analysis - Application

• 8.1 Metabolic Disorder and Obesity
  • 8.1.1 Overview
  • 8.1.2 Metabolic Disorder and Obesity Market, Revenue and Forecast to 2030 (US$ Thousand)
• 8.2 C. Difficile Infection (CDI)
  • 8.2.1 Overview
  • 8.2.2 C. Difficile Infection (CDI) Market, Revenue and Forecast to 2030 (US$ Thousand)
• 8.3 Inflammatory Bowel Disease
  • 8.3.1 Overview
  • 8.3.2 Inflammatory Bowel Disease Market, Revenue and Forecast to 2030 (US$ Thousand)
• 8.4 Others
  • 8.4.1 Overview
  • 8.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

9. Europe Microbiome Therapeutics Market Analysis - End User

• 9.1 Hospitals and Clinics
  • 9.1.1 Overview
  • 9.1.2 Hospitals and Clinics Market, Revenue and Forecast to 2030 (US$ Thousand)
• 9.2 Ambulatory Surgical Centers
  • 9.2.1 Overview
  • 9.2.2 Ambulatory Surgical Centers Market, Revenue and Forecast to 2030 (US$ Thousand)
• 9.3 Homecare
  • 9.3.1 Overview
  • 9.3.2 Homecare Market, Revenue and Forecast to 2030 (US$ Thousand)
• 9.4 Others
  • 9.4.1 Overview
  • 9.4.2 Others Market, Revenue and Forecast to 2030 (US$ Thousand)

10. Europe Microbiome Therapeutics Market - Country Analysis

• 10.1. Europe Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
  • 10.1.1 Europe Microbiome Therapeutics Market Revenue and Forecasts and Analysis - By Country
  • 10.1.2 UK
    • 10.1.2.1 UK: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.2.2 United Kingdom Europe Microbiome Therapeutics Market Breakdown by Type
      • 10.1.2.2.1 UK: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.2.3 UK: Europe Microbiome Therapeutics Market Breakdown by Application
    • 10.1.2.4 UK: Europe Microbiome Therapeutics Market Breakdown by End User
  • 10.1.3 Germany
    • 10.1.3.1 Germany: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.3.2 Germany: Europe Microbiome Therapeutics Market Breakdown by Type
      • 10.1.3.2.1 Germany: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.3.3 Germany: Europe Microbiome Therapeutics Market Breakdown by Application
    • 10.1.3.4 Germany: Europe Microbiome Therapeutics Market Breakdown by End User
  • 10.1.4 France
    • 10.1.4.1 France: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.4.2 France: Europe Microbiome Therapeutics Market Breakdown by Type
      • 10.1.4.2.1 France: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.4.3 France: Europe Microbiome Therapeutics Market Breakdown by Application
    • 10.1.4.4 France: Europe Microbiome Therapeutics Market Breakdown by End User
  • 10.1.5 Italy
    • 10.1.5.1 Italy: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.5.2 Italy: Europe Microbiome Therapeutics Market Breakdown by Type
      • 10.1.5.2.1 Italy: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.5.3 Italy: Europe Microbiome Therapeutics Market Breakdown by Application
    • 10.1.5.4 Italy: Europe Microbiome Therapeutics Market Breakdown by End User
  • 10.1.6 Spain
    • 10.1.6.1 Spain: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.6.2 Spain: Europe Microbiome Therapeutics Market Breakdown by Type
      • 10.1.6.2.1 Spain: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.6.3 Spain: Europe Microbiome Therapeutics Market Breakdown by Application
    • 10.1.6.4 Spain: Europe Microbiome Therapeutics Market Breakdown by End User
  • 10.1.7 Rest of Europe
    • 10.1.7.1 Rest of Europe: Europe Microbiome Therapeutics Market Revenue and Forecasts to 2030 (US$ Thousands)
    • 10.1.7.2 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Type
      • 10.1.7.2.1 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Therapeutics
    • 10.1.7.3 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by Application
    • 10.1.7.4 Rest of Europe: Europe Microbiome Therapeutics Market Breakdown by End User

11. Industry Landscape

• 11.1 Overview
• 11.2 Growth Strategies in Europe Microbiome Therapeutics Market

12. Company Profiles

• 12.1 YSOPIA Bioscience SA
  • 12.1.1 Key Facts
  • 12.1.2 Business Description
  • 12.1.3 Products and Services
  • 12.1.4 Financial Overview
  • 12.1.5 SWOT Analysis
  • 12.1.6 Key Developments
• 12.2 Ferring Holdings SA
  • 12.2.1 Key Facts
  • 12.2.2 Business Description
  • 12.2.3 Products and Services
  • 12.2.4 Financial Overview
  • 12.2.5 SWOT Analysis
  • 12.2.6 Key Developments
• 12.3 Enterome SA
  • 12.3.1 Key Facts
  • 12.3.2 Business Description
  • 12.3.3 Products and Services
  • 12.3.4 Financial Overview
  • 12.3.5 SWOT Analysis
  • 12.3.6 Key Developments
• 12.4 Caelus Health BV
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments
• 12.5 Vedanta Biosciences Inc
  • 12.4.1 Key Facts
  • 12.4.2 Business Description
  • 12.4.3 Products and Services
  • 12.4.4 Financial Overview
  • 12.4.5 SWOT Analysis
  • 12.4.6 Key Developments

13. Appendix

• 13.1 About The Insight Partners
• 13.2 Glossary of Terms